Table: Kyowa Kirin -9-MTH group results (IFRS)
Oct 30 (Reuters)-
Kyowa Kirin Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2025 Sep 30, 2024 Dec 31, 2025
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 349.45 362.80 478.00
(-3.7 pct) (+18.5 pct) (-3.5 pct)
Operating
Pretax 47.92 71.57 74.00
(-33.0 pct) (+11.2 pct) (-11.3 pct)
Net 32.60 55.90 57.00
(-41.7 pct) (+4.4 pct) (-4.8 pct)
EPS Basic 62.28 yen 105.20 yen 108.91 yen
EPS Diluted 62.28 yen 105.19 yen
Ann Div 58.00 yen 60.00 yen
-Q2 Div 30.00 yen 29.00 yen
-Q4 Div 29.00 yen 30.00 yen
NOTE - Kyowa Kirin Co., Ltd..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4151.T
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia